Last updated: 2026-09-06 21:42:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Atossa Therapeutics, Inc. (ATOS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.51, with a market capitalization of $24.55M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.70 to $19.35. This page covers its latest market performance, valuation, price trends and company information.
$24.55M | |
$2.51 | |
$33,480.00 | |
$1.70 | |
$2.53 | |
27.37K | |
-- | |
-- | |
$19.35 | |
$1.70 | |
-- | |
-- |
Atossa Therapeutics, Inc. (ATOS) last closed at $2.53 as of 2026-09-04 23:31:00, unchanged from the previous close of $2.53.
During the latest regular trading session, ATOS traded between $1.70 and $33,480.00, with a volume of 27.37K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Atossa Therapeutics, Inc. (ATOS) moved from $2.57 to $2.51, representing a decline of 2.33% ($0.06).
The stock traded between $2.50 and $2.58 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 49.54 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 4.6%
ATOS is currently trading at $2.51, placing it 4.6% of the way from its 52-week low of $1.70 to its 52-week high of $19.35. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 14 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Atossa Therapeutics, Inc. (ATOS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.